Smad4 is a critical component in transforming growth factor b (TGF-b) signaling and frequently mutated in pancreatic and colorectal cancers. Smad4 has two important functional domains, MH1 and MH2, that are involved in different biological processes. The MH1 domain comprises a DNA binding domain and the MH2 domain is mainly implicated in transcriptional activation and homo-and heteromeric complex formation among Smad proteins. In the present study, a total of nine Smad4 mutations at both MH1 and MH2 domains were analysed and all of them had a reduced activity to stimulate transcription of a TGF-b-responsive reporter gene. All four MH1 mutations had a markedly reduced ability to bind a consensus Smad binding element by an in vitro assay using GST fusion proteins. Among the MH2 mutations, R497H, K507Q, and R515G mutations of Smad4 gave rise to a reduced DNA binding capacity. The R497H mutation had a slightly reduced interaction with Smad2 upon activation of TGF-b receptor. However, the K507Q and R515G mutations greatly lost their ability to associate with Smad2. Using a GST pull-down assay, it was found that the Smad4 MH2 domain bearing R497H and R515G mutations had an enhanced interaction with the MH1 region of the Smad4 protein, indicating that an increased intramolecular interaction by these mutations may alleviate the DNA binding activity at the MH1 domain. Consistent with these observations, the MH2 domain with R497H mutation had an enhanced ability to inhibit TGF-b receptor-mediated transcription. In addition, the full-length R497H mutation was able to antagonize TGF-b signaling in a dominant-negative manner. Therefore, these studies revealed novel mechanisms by which the Smad4 mutations utilize to abrogate their functions in transducing the signaling of TGF-b, which plays an important role in various stages of cancer formation.
Introduction
Transforming growth factor-b (TGF-b) superfamily consists of a group of structurally related polypeptides including TGF-b, activins, bone morphogenetic proteins (BMPs), and many others that regulate a number of biological processes including cell proliferation and differentiation, apoptosis, immune modulation, and extracellular matrix production (Massague, 1998) . TGF-b signaling is initiated by ligand-induced heteromeric complex formation of cell membrane bound serine/threonine kinase receptors (Wrana et al., 1994; Massague, 1998) . Within the complex, the type II receptor kinase phosphorylates and activates the type I receptor, followed by activation of a group of Smad proteins. Smads can be divided into three functional subclasses: receptor activated Smads (R-Smads), common partner Smads (co-Smads), and inhibitory Smads (I-Smads). Smad2 and Smad3 are implicated in mediating the signals of TGF-b and activins, whereas Smad1, Smad5, and Smad8 are involved in BMP signaling (Heldin et al., 1997; Massague, 1998; Miyazono et al., 2001) . Upon ligand stimulation, R-Smads are phosphorylated by type I receptor, after which they form a heteromeric complex with co-Smad, Smad4. The Smad complex is then translocated into the nucleus in which they function as transcriptional regulators to control expression of target genes (Massague and Wotton, 2000) . On the other hand, Smad6 and Smad7 comprise another group of Smad proteins, I-Smads, that are able to inhibit signaling of TGF-b family members (Heldin et al., 1997; Massague and Wotton, 2000) .
Smad4 is the only co-Smad identified so far (Lagna et al., 1996) . It contains conserved N-and C-terminal domains (MH1 and MH2 domains, respectively) that are highly homologous to other Smad proteins. They are separated by proline-rich region referred as linker domain. The MH1 domain has intrinsic DNA binding activity to Smad-binding elements (SBEs) that contain a 5 0 -AGAC-3 0 core sequence, whereas the MH2 domain mediates many of the biological effects including interaction with other Smad proteins, transcription factors, coactivators and corepressors (Liu et al., 1997) . In basal state, the MH1 domain inhibits the transcriptional and biological activities of the MH2 domain by an intramolecular interaction . Some tumor missense mutations on the MH1 domain of Smad4, such as R100 T, can physically augment such intramolecular interaction with its MH2 domain, thus inactivating the biological function of Smad4 .
TGF-b signaling plays a complex role in carcinogenesis (Massague, 1998; de Caestecker et al., 2000) . In early stage of cancer formation, loss of TGF-b signaling is associated with the tumor suppressor activity of TGFb. At late stage of tumorigenesis, TGF-b has tumorpromoting activities and enhances invasiveness and metastasis (de Caestecker et al., 2000) . Aberrant TGFb signaling has long been implicated in cancer development mainly due to its potent inhibitory activity on cell growth and proliferation. TGF-b acts as a tumor suppressor by negative control of cell proliferation through its regulation on the expression of cyclindependent kinase inhibitors (CKIs). TGF-b has been reported to activate the transcription of a group of CKIs including p15INK4B (Hannon and Beach, 1994) , p21/WAF1/Cip1 (Datto et al., 1995; Moustakas and Kardassis, 1998) and p27Kip1 (Polyak et al., 1994) . The cytostatic activity of TGF-b is also found to be partly caused by repression of c-myc, a major growth-promoting gene (Chen et al., 2002) . Inactivating mutations of the signaling components of TGF-b pathway are frequently found in different cancers and these mutations promote the tumor cells to escape from TGF-binduced growth inhibition. Smad4 or DPC4 (deleted in pancreatic carcinoma locus 4) was originally isolated as a tumor suppressor gene and the deletion or mutation of it is found in about 50% pancreatic carcinoma Schutte et al., 1996) . Subsequently, it was found that Smad4 mutation occurs in particular tumor subsets: especially in pancreatic and colorectal cancers . Smad4 was also found to be mutated in lung, leukemia, and breast cancers . Furthermore, germline mutations in Smad4 have also been reported in Juvenile Polyposis families (Howe et al, 1998) .
Recently, Miyaki et al. analysed 176 colorectal tumors with different stages, including liver metastasis (Miyaki et al., 1999) . Several new missense mutations at the MH2 domain were reported, including R497H (with arginine replaced by histidine at residue 497), K507Q (with lysine replaced by glutamine at residue 507) and R515G (with arginine replaced by glycine at residue 515). The R497H and K507Q mutations were identified in both primary colon cancer and metastatic lesion in liver and accompanied by a loss of heterozygosity (Miyaki et al., 1999) . The R515G mutation was found in the intramucosal carcinoma of colon without loss of heterozygosity (Miyaki et al., 1999) . In order to characterize the molecular properties of Smad4 mutations derived from human cancers, we determined the functional consequences of some of the mutations at the MH1 and MH2 domains of Smad4. Using both in vitro and in vivo experiments, we demonstrated that the R497H, K507Q, and R515G mutations had a reduced DNA binding ability and a loss of transactivating activity in response to TGF-b signaling.
Furthermore, we observed an increased intramolecular interaction between the MH1 domain and the MH2 domains with R497H and R515G mutations. Such an enhanced interaction may interfere with the intrinsic DNA binding activity of the MH1 domain. This study, therefore, provides useful insights into the mechanisms by which disruption of TGF-b signaling pathway by Smad4 mutations leads to cancer formation.
Results

Loss of TGF-b-induced transcriptional activation by tumor-derived mutations of Smad4
In order to determine the functional consequences of Smad4 mutations found in human cancers, we analysed the activity of these mutations in transcriptional activation. Four MH1 mutations (L43 V, R100 T, P102L, and P130S) and five MH2 mutations (D351H, R361C, R497H, K507Q, and R515G) were generated by a PCR-based mutagenesis. These mutations were frequently pancreatic and colon cancers Miyaki et al., 1999) . These constructs were subsequently used in transient transfection into MDA-MB468, a breast cancer cell line with homozygous Smad4 deletion and insensitive to TGF-b . In addition, a TGF-b-responsive luciferase reporter that contains six repeats of SBE identified in the mouse Smad7 promoter (Nagarajan et al., 1999) with a TATA box was cotransfected into these cells. As shown in Figure 1 , we did not observe significant increases in luciferase activity when Smad2, Smad4, or a constitutively active TGF-b type I receptor (CA-ALK5) was individually transfected into MDA-MB468 cells. However, coexpression of Smad2, Smad4, and CA-ALK5 was able to significantly activate the promoter. Nine Smad4 mutations in mammalian expression vector were transiently transfected with a SBE-containing luciferase reporter into MDA-MB468 cells. Smad2, Smad4, and the constitutively active ALK-5 (CA-ALK5) were also expressed as indicated. A SV40-driven renilla luciferase was used to monitor the transfection efficiency. Luciferase activities were measured 48 h after transfection. The fold changes in luciferase activity as compared with that in the empty vector-transfected cells (set to 1) are shown after being normalized by renilla luciferase activity. At least three independent experiments were performed with similar results. Data are shown as mean7s.d.
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This finding confirmed that MDA-MB468 is insensitive to TGF-b signaling and expression of Smad2 and Smad4 is able to restore its response to TGF-b receptor activation. Next, we compared the transcriptional activities of all nine Smad4 mutants to that of wildtype Smad4. All these mutations had a significantly compromised activity to transactivate the TGF-bresponsive reporter gene (Figure 1 ). These studies indicated that these mutations would lead to reduced transactivating activities that are responsible for the loss of TGF-b responsiveness of the tumor cells bearing these mutations.
Analyses of the DNA binding activities of Smad4 mutations
The MH1 domains of R-Smads and Co-Smad possess an intrinsic DNA binding activity via a highly conserved b-hairpin loop . To determine how tumor-derived mutations of Smad4 affect the DNA binding activity, we generated GST-fusion proteins that contain full-length Smad4 with various missense mutations and these proteins were analysed in electrophoretic mobility shift assay (EMSA). A consensus SBE identified in the mouse Smad7 promoter (Nagarajan et al. 1999) was used in EMSA to characterize the DNA binding. These GST-fusion proteins was produced from BL21 Escherichia coli cells and verified by SDS-PAGE analysis ( Figure 2a ). Compared with wild-type Smad4 protein, the MH1 Smad4 mutants including L43V, R100T, and P102L completely lost their DNA binding activity ( Figure 2b ). The P130S mutant that carried a mutation at the C-terminal end of the MH1 domain also showed a markedly reduced DNA binding activity ( Figure 2b ). These findings are in agreement with studies by other groups' reports, indicating that missense mutations of Smad4 proteins in the MH1 domain fail to bind DNA (Moren et al., 2000) . We analysed five Smad4 mutations that occur at the MH2 domain including D351H, R361C, R497H, K507Q, and R515G. To our surprise, we found that the R497H mutation markedly attenuated the DNA binding activity of Smad4 (Figure 2b ), although the MH2 domain is not directly involved in DNA binding from structural studies (Shi et al., 1997) . In addition to R497H mutation, K507Q and R515G mutations also had compromised abilities to bind the SBE. In order to verify our finding on the reduced DNA binding activity of Smad4 R497H mutation, we expressed the wild-type Smad4 and the R497H mutant in HEK293 cells and the nuclear extract was subjected to EMSA using the same probe as in Figure 2 . The expression of these proteins in the nuclear extract was confirmed by Western blotting analysis with an antiFlag antibody, as both of them contain a Flag tag at their N-terminal ends ( Figure 3a , lanes 5-8). The nuclear extracts were used in EMSA and the anti-Flag antibody was used in a 'supershift' assay to identify the Smad4-containing complex. As shown in Figure 3b , the anti-Flag antibody was not able to cause any shifting in the nuclear extracts from vector or CA-ALK5 transfection. However, in the samples derived from cotransfection of wild-type Smad4 and CA-ALK5, a Smad4-binding complex was formed (Figure 3b , lane 5) and the anti-Flag antibody was able to lead to an obvious supershift ( Figure 3b , lane 6). When the cells were transfected with CA-ALK5 and the R497H mutant of Smad4, the Smad4-containing binding complex could not be detected (Figure 3b , lanes 7 and 8), confirming that the R497H mutation has a decreased activity in DNA binding.
R497H, K507Q, and R515G mutants of Smad4 have reduced interaction with Smad2 upon activation of TGT-b receptor
The MH2 domains of Smad2 and Smad4 are involved in the formation of homo-and heteromeric complexes among the Smad proteins. Smad4 plays a central role in the complex formation that is required for nuclear translocation and gene transcription by Smad complex (Liu et al., 1997) . As R497H, K507Q, and R515G mutations occur at the MH2 domain, we examined the effect of these mutations on the interaction of Smad4 with Smad2 upon TGF-b receptor activation. The Flag tagged wild-type or Smad4 mutants were coexpressed 
R497H and R515G mutations have an increased intramolecular interaction within Smad4
R497H, K507Q, and R515G are missense mutations in the MH2 domain, although they have an obviously reduced DNA binding activity (Figure 2 ). It has been reported that the MH1 domain of Smad4 has an autoinhibitory ability to the MH2 domain by intramolecular interaction . We hypothesized that these MH2 mutations might increase their intramolecular interaction between MH1 and MH2 domains and thus result in a compromised DNA binding capacity. To address this hypothesis, we performed a GST pull-down assay with the expressed Smad4 proteins. We generated a GST-fusion protein that contains the first 310 amino-acid residues of Smad4 ( Figure 5a ). This fusion protein covers the MH1 domain and the linker region of the wild-type Smad4. The GST fusion proteins were then bound to GSH-coupled Sepharose beads. HEK293 cells were transiently expressed with the MH2 domains of the wild-type and mutated Smad4. The MH2 domains of these Smad4 constructs all contain a myc tag at their N-termini as confirmed by Western blotting analysis with an anti-myc antibody (Figure 5b, top panel) . The cell lysates were subsequently incubated with GST or the GST-fusion proteins with N-terminal part of Smad4. The incubation was subjected to vigorous wash to reduce nonspecific binding, followed by Western blotting analysis with an anti-myc antibody to detect the myc-tagged MH2 domains. As shown in Figure 5b , GST alone was not able to pull down significant amount of any of the MH2 domains (middle panel). The fusion protein containing the MH1 and linker regions of Smad4 was able to weakly associate with the MH2 domains of the wild-type Smad4 as well as the K507Q mutant (lanes 1 and 3) . However, the interaction of the MH1-linker region to the MH2 domains that contains the R497H and R515G mutations was largely increased (lanes 2 and 4). These data clearly indicated that the R497H and R515G mutations are able to enhance the intramolecular interaction within Smad4 and such an enhanced interaction may be responsible for the reduced DNA binding capacity of these two mutations.
MH2 domain of R497H had an enhanced activity to block TGF-b signaling
Our studies indicated that the R497H mutation led to an increased intramolecular interaction between the MH1 and MH2 domains of Smad4. It was, therefore, hypothesized that such an increased interaction would confer the MH2 domain of R497H mutation with an enhanced activity to inhibit TGF-b signaling. To address this hypothesis, the MH2 domains of the wildtype Smad4 and the R497H mutant was expressed in HEK293 cells, which were chosen as these cells contain intact TGF-b signal pathway and have been extensively used to analyse TGF-b-mediated transcriptional regulation (Nagarajan and Chen, 2000) . When a constitutively active TGF-b type I receptor (CA-ALK-5) was expressed in these cells, it was able to strongly stimulate the transcription of a TGF-b-responsive reporter as used in Figure 1 . As shown in Figure 6 , cotransfection of the MH2 domain of wild-type Smad4 was able to partly inhibit the CA-ALK5-induced transcriptional stimulation. Consistent with our hypothesis, overexpression of the MH2 domain of R497H mutant appeared to have an enhanced activity to inhibit the receptor-stimulated transcription.
R497H mutation had no effect on nuclear localization upon TGF-b signaling
Activation of TGF-b signaling leads to heteromeric complex formation between Smad2/3 and Smad4 and allows for the complex to translocate into the nucleus. To address whether or not the R497H mutation has any effect on nuclear translocation, we used immunofluorescence staining to analyse the intracellular distribution of Smad4 proteins. Both the wild-type and R497H mutant were expressed in HaCaT cells, which are human keratinocytes responsive to TGF-b treatment. As shown in Figure 7 , both the wild type and R497H mutant of Smad4 proteins were localized in cytoplasm before TGF-b treatment. However, TGF-b treatment was able to cause nuclear translocation of both proteins. This study indicated that the R497H mutation does not compromise its capacity to traffic into nucleus upon TGF-b signaling. This is consistent with the fact that HEK293 cells were transiently transfected with plasmids expressing MH2 domains as indicated. Cell extracts (5% of the amount to be used in GST pull-down assay) were used in Western blotting to determine the expression level of the myc-tagged MH2 domains of wild-type and R497 H mutation of Smad4 (upper panel). GST pulldown assay to determine the interaction of MH2 domain with MH1 -linker region of Smad4. Cell lysates were incubated with Sepharose beads coupled with GST or GST-Smad4 (1-310 aa). The bound proteins were analysed by SDS-PAGE and Western blotting using an anti-Myc antibody to detect the myc-tagged MH2 domains of Smad4 proteins MH2 mutation of Smad4 C Kuang and Y Chen this mutation is not at the region that contains the nuclear localization signal for Smad4 (Xiao et al., 2003) .
R497H mutation had a dominant-negative effect to inhibit TGF-b-mediated transcription
In some cancers, mutations of Smad4 only occur in one allele without loss of the wild-type allele (Miyaki et al., 1999) . In this case, the Smad4 mutation may serve as a dominant-negative protein to abrogate the functionality of the normal allele. To aid in understanding this hypothesis, we analysed the ability of R497H mutation to affect TGF-b signaling. As shown in Figure 8 , expression of CA-ALK5 in HEK293 cells was able to greatly stimulate the SBE reporter gene. When various amounts of wild-type Smad4 was coexpressed, they had no effect on the transcription stimulated by TGF-b receptor. However, when the R497H mutant of Smad4 was expressed, it was able to inhibit TGF-b-mediated transcriptional activation in a dose-dependent manner. Therefore, these data indicated that the R497H mutant may serve as a dominant-negative protein to block the function of the wild-type Smad4 partner to transduce the signals downstream of TGF-b receptor in cancer cells.
Discussion
In this study, we have analysed the biological consequences of various missense mutations of Smad4 protein identified in different human cancers. All the nine tumor-derived Smad4 mutations have a reduced activity to transactivate a TGF-b responsive reporter gene, indicating that all these mutations have a compromised activity in mediating the transcriptional regulation by TGF-b signaling pathway. Consistent with the structural studies of Smad proteins, all the mutants at the MH1 domain had a reduced activity to bind SBE. However, we found that several mutations at the MH2 domain, R497H, K507Q, and R515G, had a marked reduction in DNA binding. Further studies indicated that these mutations also affect the interaction of Smad4 with Smad2 at different levels. Among these mutations, R497H and R515G had an enhanced intramolecular interaction of the MH2 domain with the MH1 and linker region of Smad4, indicating that such an increased interaction may underlie the decreased DNA binding capacity of these mutants. In agreement with this hypothesis, overexpression of the MH2 domain with R497H mutation had an enhanced capacity to inhibit TGF-b signaling. This could be explained by disruption of the binding of the wild-type Smad4 with SBE through an increased interaction of the MH2 domain with R497H mutation with the MH1 domain of the wild-type proteins. Furthermore, expression of the full-length Smad4 with R497H mutation was able to antagonize TGF-b signaling in a dominant-negative manner. This is consistent with clinical observation in which only one allele of Smad4 gene is affected in some cancer samples (Miyaki et al., 1999) . However, it remains to be determined if other Smad4 mutations can serve as dominant-negative mutants to disrupt TGF-b function. The structure of the Smad4 MH2 domain consists of a central b-sandwich with a three-helix bundles (H3, H4, and H5 helices) on one end and a collection of three large loops and an alpha helix (HI) on the other (Shi et al., 1997) . The missense mutation of Smad4 R497H occurs at the H4 helix with the arginine residue replaced by histidine. At this position, arginine is not exposed to solvent but 60-90% buried in the helix bundle structure Figure 8 Dominant-negative effect of Smad4 R497 H mutant. HEK293 cells were transfected with CA-ALK5 to stimulate TGF-b signaling shown as an activation of a SBE-containing luciferase reporter. Different amounts (50-800 ng/transfection) of full-length Smad4 or R497 H mutant expression plasmids were cotransfected as indicated. A SV40-driven renilla luciferase was used to delineate the transfection efficiency. Luciferase activities were measured 48 h after transfection. The fold changes of luciferase activity were normalized by renilla luciferase activity. Data are shown as mean7s.d. Figure 7 Nuclear translocation of wild type and R497 H Smad4. Human keratinocyte HaCaT cells were transfected with Flagtagged wild type or R497 H Smad4 as indicated. At 48 h after transfection, cells were treated with or without TGF-b1 for 1 h before fixation. An anti-Flag antibody and a secondary Aliex-546 conjugated anti-mouse antibody were used to determine the expression of Smad4 (in red color). Nuclear staining was performed with Hoeschst33342 (in blue color). Note the nuclear translocation of both Smad4 proteins after TGF-b1 treatment MH2 mutation of Smad4 C Kuang and Y Chen (Shi et al., 1997) . Since histidine has a relatively bulky side chain, this substitution would probably disrupt the packing between the three-helix bundles and the bsandwich, as there is little space in this part of the hydrophobic core. Thus, the mutation may change protein conformation, which in turn augments the association between the MH2 domain and the MH1 region of the protein. The K507Q mutation is located at the beginning of L3 loop and this residue is buried in the central b-sandwich (Shi et al., 1997) . Replacement of the positively charged lysine by neutral glutamine may change the ionic interaction of this residue with other amino acids, resulting in conformational change that disrupts its association with Smad2. On the other hand, the R515G mutation is at the middle of L3 loop (Shi et al., 1997) . The L3 loop of Smad proteins has been proposed to be implicated in Smad-receptor interaction (Lo et al., 1998) and trimerization of Smad proteins (Chacko et al, 2001) . Mutation of R515G at this region may explain its reduced interaction with Smad2 upon TGF-b signaling.
The conserved MH2 domain of Smad4 is implicated in mediating many of the biological effects of Smad4 and these effects are inhibited by an intramolecular interaction with the MH1 domain of the protein . This is consistent with the finding that the autoinhibitory function of the MH1 domain is enhanced in a missense mutation in the MH1 domain, R100 T, indicating that one single amino-acid substitution is sufficient to change the strength of intramolecular interaction. In our study, two MH2 mutations of Smad4, R497H, and R515G, appear to enhance this intramolecular interaction. The enhancement of intramolecular interaction between the MH1 and MH2 domains may stabilize protein in a tight conformation and prevent the MH1 domain from binding to DNA. The sequence-specific DNA binding of Smads is achieved by a highly conserved 11-residue b-hairpin at the MH1 domain . There are three important residues from this b-hairpin that make specific hydrogen bonds to the SBE . The structural basis for the interaction between MH1 and MH2 domains are currently unknown. Our studies here indicated that the MH2 domain, through its intramolecular interaction with the MH1 domain, is also involved in the regulation of the DNA binding activity of the MH1 domain. Therefore, studies on Smad4 mutations would further our understanding on the structure/function relationship of this critical protein in transducing the signals of TGF-b family receptors.
Materials and methods
Reagents
Dulbecco's modified Eagles medium (DMEM) and Minimum Essential medium (MEM) were purchased from Gibco (Carlsbad, CA, USA). Fetal bovine serum (FBS), penicillin/ streptomycin, and trypsin were purchased from Bio Whittaker (Walkersville, MD, USA). Glutathione, protease inhibitor cocktail, and anti-Flag antibody (M2) were provided by Sigma (St Louis, MO, USA). Anti-myc antibody (9E10) and Expand High Fidelity PCR system were purchased from Roche (Indianapolis, IN, USA).
Cell cultures and transient transfection
The human embryonic kidney (HEK293) and human keratinocyte HaCaT cells were cultured in DMEM medium supplemented with 10%FBS and 1% penicillin/streptomycin. The human breast carcinoma cell line, MDA-MB468 was a kind gift from Dr H Nakshatri (Indiana University School of Medicine) and was cultured in MEM medium supplemented with 10% FBS, 1% L-glutamine and penicillin/streptomycin. Transient transfection was performed using the calcium phosphate method for HEK293 cells and Superfect reagents (Qiagen, Valencia, CA, USA) for MDA-MB 468 cells.
Site-directed mutagenesis
The point-mutation constructs of Smad4 were created by using a PCR-based mutagenesis method. Briefly, two PCR fragments were first generated with a point mutation induced by the PCR primer at one end. These two fragments were annealed and used as a template for PCR with two outside primers. The PCR fragments were cloned using TOPO TA cloning system (Invitrogen, Carlsbad, CA, USA), and then subcloned into mammalian expression vector pcDNA3 (Invitrogen, Carlsbad, CA, USA). All site-directed mutations were confirmed by DNA sequencing.
Plasmid and GST-fusion proteins
The myc-tagged Smad2 has been described previously (Chen et al., 1997; Nagarajan et al., 1999) . The MH2 domain of wildtype Smad4 and R497H mutant were generated by Expended Hi-fidelity PCR System (Roche, Indianapolis, IN, USA) and subcloned into pCS2-myc vector which has 6 myc tag repeats in N-terminal end. All the glutathione-S-transferase (GST) fusion constructs were generated by in-frame fusion of the fulllength Smad4 cDNA with pGEX-4T2 (Amersham Biosciences, Piscataway, NJ, USA) as previously described (Li et al., 2001) . The constructs were transformed and expressed as GST fusion proteins in E. coli BL21 strain (Amersham Biosciences, Piscataway, NJ, USA).
Luciferase assay
MDA-MB468 cells were seeded in six-well tissue culture plate at a density of 2 Â 10 5 cells/ml. A SV40-driven renilla-luciferase was cotransfected to serve as an internal control for transfection efficiency. After transfection, cells were incubated for 24-48 h to allow expression of proteins from the transfected plasmids. Cell lysates were then prepared and the luciferase activities were determined with Promega Dual Luciferase assay according to the manufacturer's instruction. The data were represented as the relative light unit/s.
Electrophoretic mobility shift assay
Double-stranded oligonucleotides were labeled with [g-32 P]dATP by T4 polynucleotide kinase. The probes (about 5 Â 10 4 c.p.m.) were incubated with about 0.2 mg of GST or wild-type and mutant GST-Smad4 fusion proteins in a buffer containing a final concentration of 4% glycerol, 10 mM Tris (pH 7.5), 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM dithiothreitol, 50 mM NaC1, and 0.1 mg/m1 poly(dI-dC). For supershift EMSA, the Flag-tagged Smad4 expression plasmids were transfected into HEK293 cells 24 h before the experiment. The MH2 mutation of Smad4 C Kuang and Y Chen nuclear extracts were prepared as described (Andrews and Faller, 1991) . About 0.1 mg anti-Flag antibody was incubated with nuclear extracts at room temperature for 10 min. The reaction was incubated on ice for another 30 min, separated by 6% nondenaturing polyacrylamide gel in 0.5 Â TBE buffer and detected by autoradiography.
Immunoprecipitation and Western blotting analysis
HEK 293 cells were transfected with combinations of various DNA plasmids. At 36 h after transfection, cells were harvested and lysed in RIPA buffer (150 mM NaCl, 20 mM Tris with pH at 8.0, 10 mM NaH 2 PO 4 , 5 mM EDTA, 10% glycerol, 1% NP-40, 1% sodium deoxycholate acid and 1% SDS) containing protease and phosphatase inhibitors. The cell lysates were precleared by proteinA/G Agarose (Oncogene, San Diego, CA, USA), mixed with the anti-Flag monoclonoal antibody, rotated for 4 h at 41C. The beads were washed and subjected to SDS-PAGE and Western blotting with anti-myc 9E10 antibody (Roche, Indianapolis, IN, USA).
Glutathione S-transferase (GST) pull-down assay
GST-fusion protein that contains the first 310 amino-acid residues was generated by in-frame ligation of the corresponding Smad4 fragment with pGEX-4T2 vectors. The purified GST proteins were bound to GSH-agarose bead (Sigma) according to the manufacturer's instruction (Sigma, St Louis, MI, USA). The beads were stored in PBS containing 0.01 mM sodium azide at 41C. For GST pull-down assay, HEK293 cells were transfected with myc-tagged Smad4 MH2 plasmids. At 48 h after transfection, cells were lysed in RIF buffer (50 mM Tris with pH 7.4, 10% glycerol, 200 mM NaCl, 2.5 mM MgCl 2 , 1% NP-40) containing protease inhibitors. The protein concentrations were measured by using BioRad protein assay. A portion of cell lysates were separated by SDS-PAGE, followed by Western blot analysis with anti-myc antibody to determine the expression level of the MH2 domains. Before the GST pull-down assay, the GST containing beads were rigorously washed. The beads were then incubated with cell lysates (with a total protein amount of about 500 mg) at 41C for 3 h, followed by extensive wash with RIF buffer. The proteins bound to the beads were eluted by boiling in SDS-gel loading buffer containing 20% b-mecaptoethanol. The eluents were separated by electrophoresis on 15% SDS-PAGE, followed by Western blot with an anti-myc antibody.
Immunofluorescence staining of cells
HaCaT cells were cultured on coverslips in six-well plates. Cells were treated with TGF-b1 (5 ng/ml) for 1 h before fixation, which was performed with 3.7% formaldehyde and 0.1% Triton-100. The cells were incubated with anti-Flag antibody (1 mg/ml), washed, and then incubated with Aliex-546 conjugated anti-mouse antibody (Molecular Probes). Nuclear staining was performed with Hoeschst33342 (Sigma). The coverslips were mounted and the stained cells were analysed by a fluorescence microscope (Nikon Eclipse E600) with a digital camera (Nikon Coolpix 950). 
